Characteristics of the study participants
| Characteristics . | BMT survivors (n = 2430), n (%) . | Non-BMT comparison group (n = 780), n (%) . | P value . |
|---|---|---|---|
| Age at study participation | |||
| Median (range) | 63 (20-91) | 62 (21-88) | .17 |
| <65 y | 1317 (54.2) | 448 (57.4) | .11 |
| ≥65 y | 1113 (45.8) | 332 (42.6) | |
| Sex | |||
| Female | 1147 (47.2) | 502 (64.4) | <.0001 |
| Race/ ethnicity | |||
| African American | 131 (5.4) | 20 (2.6) | <.0001 |
| Hispanic | 257 (10.6) | 44 (5.6) | |
| Non-Hispanic White | 1855 (76.3) | 686 (88.0) | |
| Other | 187 (7.7) | 30 (3.8) | |
| Annual household income | |||
| <$50 000 | 649 (26.7) | 142 (18.2.0) | <.0001 |
| $50 000-74 999 | 371 (15.3) | 146 (18.7) | |
| ≥$75 000 | 1069 (44.0) | 423 (54.2) | |
| Missing | 341 (14.0) | 69 (8.9) | |
| Education | |||
| <High school | 377 (15.5) | 80 (10.3) | <.0001 |
| High school to college | 883 (36.4) | 262 (33.8) | |
| ≥College | 1169 (48.1) | 433 (55.9) | |
| Have insurance | |||
| Yes | 2381 (98.0) | 757 (97.7) | .55 |
| Contact with COVID-19 test positive individuals (family members/friends/at work) | |||
| Yes | 1081 (44.5) | 442 (56.7) | <.0001 |
| Always wears mask | |||
| Yes | 2146 (88.3) | 662 (84.9) | .01 |
| Always stays 6 feet away | |||
| Yes | 1728 (71.1) | 464 (59.5) | <.0001 |
| Always washes hands | |||
| Yes | 1208 (49.7) | 322 (41.3) | <.0001 |
| Chronic health conditions (severe/life-threatening) | |||
| No | 190 (7.8) | 159 (20.4) | <.01 |
| Grade 1 | 156 (6.4) | 86 (11.0) | |
| Grade 2 | 736 (30.3) | 298 (38.3) | |
| Grade 3 | 925 (38.1) | 182 (23.4) | |
| Grade 4 | 423 (17.4) | 54 (6.9) | |
| COVID-19 test positive | |||
| Yes | 121 (5.0) | 47 (6.0) | .25 |
| Employment | |||
| Employed | 1038 (42.9) | 456 (58.7) | <.0001 |
| Not employed | 401 (16.6) | 52 (6.7) | |
| Retired | 981 (40.5) | 269 (34.6) | |
| Age at BMT (y) | |||
| Median (range) | 46 (0-78) | ||
| <45 y | 1136 (46.7) | ||
| 45-64 y | 1086 (44.7) | ||
| ≥65 y | 208 (8.6) | ||
| BMT type | |||
| Autologous | 1117 (46.0) | ||
| Allogeneic without chronic GvHD | 610 (25.1) | ||
| Allogeneic with chronic GvHD | 703 (28.9) | ||
| BMT survivors follow-up (y) | |||
| Median (range) | 14 (6-46) | ||
| <10 y | 571 (23.5) | ||
| 10-19 y | 1122 (46.2) | ||
| ≥20 y | 737 (30.3) | ||
| BMT survivors primary cancer | |||
| Leukemia | 1006 (41.4) | ||
| Lymphoma | 794 (32.7) | ||
| Plasma cell dyscrasias | 448 (18.4) | ||
| Other | 182 (7.5) | ||
| BMT survivors conditioning intensity | |||
| Myeloablative conditioning | 1610 (66.3) | ||
| Nonmyeloablative/ reduced intensity conditioning | 820 (33.7) | ||
| Disease status at BMT | |||
| High-risk | 1061 (43.7) | ||
| Characteristics . | BMT survivors (n = 2430), n (%) . | Non-BMT comparison group (n = 780), n (%) . | P value . |
|---|---|---|---|
| Age at study participation | |||
| Median (range) | 63 (20-91) | 62 (21-88) | .17 |
| <65 y | 1317 (54.2) | 448 (57.4) | .11 |
| ≥65 y | 1113 (45.8) | 332 (42.6) | |
| Sex | |||
| Female | 1147 (47.2) | 502 (64.4) | <.0001 |
| Race/ ethnicity | |||
| African American | 131 (5.4) | 20 (2.6) | <.0001 |
| Hispanic | 257 (10.6) | 44 (5.6) | |
| Non-Hispanic White | 1855 (76.3) | 686 (88.0) | |
| Other | 187 (7.7) | 30 (3.8) | |
| Annual household income | |||
| <$50 000 | 649 (26.7) | 142 (18.2.0) | <.0001 |
| $50 000-74 999 | 371 (15.3) | 146 (18.7) | |
| ≥$75 000 | 1069 (44.0) | 423 (54.2) | |
| Missing | 341 (14.0) | 69 (8.9) | |
| Education | |||
| <High school | 377 (15.5) | 80 (10.3) | <.0001 |
| High school to college | 883 (36.4) | 262 (33.8) | |
| ≥College | 1169 (48.1) | 433 (55.9) | |
| Have insurance | |||
| Yes | 2381 (98.0) | 757 (97.7) | .55 |
| Contact with COVID-19 test positive individuals (family members/friends/at work) | |||
| Yes | 1081 (44.5) | 442 (56.7) | <.0001 |
| Always wears mask | |||
| Yes | 2146 (88.3) | 662 (84.9) | .01 |
| Always stays 6 feet away | |||
| Yes | 1728 (71.1) | 464 (59.5) | <.0001 |
| Always washes hands | |||
| Yes | 1208 (49.7) | 322 (41.3) | <.0001 |
| Chronic health conditions (severe/life-threatening) | |||
| No | 190 (7.8) | 159 (20.4) | <.01 |
| Grade 1 | 156 (6.4) | 86 (11.0) | |
| Grade 2 | 736 (30.3) | 298 (38.3) | |
| Grade 3 | 925 (38.1) | 182 (23.4) | |
| Grade 4 | 423 (17.4) | 54 (6.9) | |
| COVID-19 test positive | |||
| Yes | 121 (5.0) | 47 (6.0) | .25 |
| Employment | |||
| Employed | 1038 (42.9) | 456 (58.7) | <.0001 |
| Not employed | 401 (16.6) | 52 (6.7) | |
| Retired | 981 (40.5) | 269 (34.6) | |
| Age at BMT (y) | |||
| Median (range) | 46 (0-78) | ||
| <45 y | 1136 (46.7) | ||
| 45-64 y | 1086 (44.7) | ||
| ≥65 y | 208 (8.6) | ||
| BMT type | |||
| Autologous | 1117 (46.0) | ||
| Allogeneic without chronic GvHD | 610 (25.1) | ||
| Allogeneic with chronic GvHD | 703 (28.9) | ||
| BMT survivors follow-up (y) | |||
| Median (range) | 14 (6-46) | ||
| <10 y | 571 (23.5) | ||
| 10-19 y | 1122 (46.2) | ||
| ≥20 y | 737 (30.3) | ||
| BMT survivors primary cancer | |||
| Leukemia | 1006 (41.4) | ||
| Lymphoma | 794 (32.7) | ||
| Plasma cell dyscrasias | 448 (18.4) | ||
| Other | 182 (7.5) | ||
| BMT survivors conditioning intensity | |||
| Myeloablative conditioning | 1610 (66.3) | ||
| Nonmyeloablative/ reduced intensity conditioning | 820 (33.7) | ||
| Disease status at BMT | |||
| High-risk | 1061 (43.7) | ||